Oncotelic Announces Successful Completion of the Safety Evaluation of a TGF-β Inhibitor (OT-101) and IL-2 (Aldesleukin) in Phase 1 Combination Trial in Solid Tumor Cancers
Safety, AML, Intelligence, Cancer, Interleukin 2, CA4P, DIPG, Private Securities Litigation Reform Act, Therapy, Form 10-K, Colorectal cancer, Cocaine, Acute respiratory distress syndrome, Kawasaki, CEO, Immune system, RNA, Glioma, Virology, Pointr, Food, Risk, Trial of the century, Severe acute respiratory syndrome coronavirus 2, CA, Trial, COVID-19, Treatment, Immunotherapy, Oxigen Services, Food and Drug Administration Amendments Act of 2007, Diffuse intrinsic pontine glioma, Forward-looking statement, Optimism, Annual report, Acquisition, Company, GLOBE, The Trial, SEC, Lond, Communication, Survival, Pancreatic cancer, Patient, Kawasaki disease, Melanoma, Glioblastoma, New, Pharmaceutical industry
The 140 mg/m2 dose was shown to be the optimal dose for OT-101 in the prior trial targeting pancreatic cancer, melanoma, and colorectal cancer (P001).
Key Points:
- The 140 mg/m2 dose was shown to be the optimal dose for OT-101 in the prior trial targeting pancreatic cancer, melanoma, and colorectal cancer (P001).
- Therefore, the Company believes that increasing the dose above 140 mg/m2 should further enhance the clinical activity of OT-101.
- We are excited to see this clear demonstration of safety for the OT-101/IL-2 combination, noted Dr. Vuong Trieu, CEO of Oncotelic.
- Our analysis to date suggests that the OT-101/IL-2 combination could further improve the cure rate of these cancers.